

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

SENATE BILL 367

52ND LEGISLATURE - STATE OF NEW MEXICO - FIRST SESSION, 2015

INTRODUCED BY

Michael S. Sanchez

AN ACT

RELATING TO PROFESSIONAL LICENSURE; AMENDING AND REPEALING
SECTIONS OF THE OPTOMETRY ACT TO MAKE CHANGES TO BOARD POWERS
AND TO PROVIDE OPTOMETRISTS WITH GREATER PRESCRIBING POWERS;
AMENDING A SECTION OF THE NEW MEXICO DRUG, DEVICE AND COSMETIC
ACT TO INCLUDE OPTOMETRISTS AS PRESCRIBING PRACTITIONERS.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

SECTION 1. Section 61-2-2 NMSA 1978 (being Laws 1973,
Chapter 353, Section 2, as amended) is amended to read:

"61-2-2. DEFINITIONS.--As used in the Optometry Act:

A. "practice of optometry" means:

(1) the employment of any subjective or
objective means or methods, including but not limited to the
use of lenses, prisms, autorefractors or other automated
testing devices, and includes the prescription or

.199044.2

underscoring material = new
~~[bracketed material] = delete~~

1 administration of drugs for the purpose of diagnosing the
2 visual defects or abnormal conditions of the human eye and its
3 adnexa;

4 (2) the employing, adapting or prescribing of
5 preventive or corrective measures, including but not limited to
6 lenses, prisms, contact or corneal lenses or other optical
7 appliances, ocular exercises, vision therapy, vision training
8 and vision rehabilitation services, and includes the
9 prescription or administration of all drugs rational for the
10 correction, relief or referral of visual defects or abnormal
11 conditions of the human eye and its adnexa; and

12 (3) does not include the use of surgery or
13 injections in the treatment of eye diseases except for the use
14 of the following types of in-office minor surgical procedures:

15 (a) non-laser removal, destruction or
16 drainage of superficial eyelid lesions and conjunctival cysts;

17 (b) removal of nonperforating foreign
18 bodies from the cornea, conjunctiva and eyelid;

19 (c) non-laser corneal debridement,
20 culture, scrape or anterior puncture, not including removal of
21 pterygium, corneal biopsy or removal of corneal neoplasias;

22 (d) removal of eyelashes; and

23 (e) probing, dilation, irrigation or
24 closure of the tear drainage structures of the eyelid; scalpel
25 use is to be applied only for the purpose of use on the skin

underscored material = new
[bracketed material] = delete

1 surrounding the eye;

2 B. "ophthalmic lens" means a lens that has a
3 spherical, cylindrical or prismatic value, is ground pursuant
4 to a prescription and is intended to be used as eyeglasses;

5 C. "contact lens" means a lens to be worn on the
6 anterior segment of the human eye;

7 D. "prescription" means a written order by an
8 optometrist or a physician for an individual patient for:

9 (1) ophthalmic lenses;

10 (2) contact lenses; or

11 (3) a [~~topical ocular pharmaceutical agent or~~
12 ~~an oral~~] pharmaceutical agent that is regulated pursuant to the
13 New Mexico Drug, Device and Cosmetic Act;

14 E. "eyeglasses" means an exterior optical device
15 using ophthalmic lenses for the correction or relief of
16 disturbances in and anomalies of human vision; and

17 F. "board" means the board of optometry."

18 SECTION 2. Section 61-2-6 NMSA 1978 (being Laws 1973,
19 Chapter 353, Section 5, as amended) is amended to read:

20 "61-2-6. ORGANIZATION--MEETINGS--COMPENSATION--POWERS AND
21 DUTIES.--

22 A. The board shall annually elect a [~~chairman~~
23 chair, a vice [~~chairman~~] chair and a secretary-treasurer; each
24 shall serve until [~~his~~] a successor is elected and qualified.

25 B. The board shall meet at least annually for the

.199044.2

underscored material = new
[bracketed material] = delete

1 purpose of examining candidates for licensure. Special
2 meetings may be called by the [~~chairman~~] chair and shall be
3 called upon the written request of a majority of the board
4 members. A majority of the board members currently serving
5 constitutes a quorum.

6 C. Members of the board may be reimbursed as
7 provided in the Per Diem and Mileage Act but shall receive no
8 other compensation, perquisite or allowance.

9 D. The board has the sole authority to determine
10 what constitutes the practice of optometry in accordance with
11 the provisions of the Optometry Act and has sole jurisdiction
12 to exercise any other powers and duties under that act. The
13 board may issue advisory opinions and declaratory rulings
14 pursuant to the Optometry Act and rules promulgated pursuant to
15 that act. Nothing in the Optometry Act shall be construed to
16 allow any agency, board or other entity of the state other than
17 the board to determine what constitutes the practice of
18 optometry.

19 [~~D.~~] E. The board shall:

20 (1) administer and enforce the provisions of
21 the Optometry Act;

22 (2) adopt, publish and file, in accordance
23 with the Uniform Licensing Act and the State Rules Act, all
24 rules [~~and regulations~~] for the implementation and enforcement
25 of the provisions of the Optometry Act;

.199044.2

underscoring material = new
~~[bracketed material] = delete~~

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

(3) adopt and use a seal;

(4) administer oaths and take testimony on matters within the board's jurisdiction;

(5) keep an accurate record of meetings, receipts and disbursements;

(6) keep a record of examinations held, together with the names and addresses of persons taking the examinations and the examination results. Within thirty days after an examination, the board shall give written notice to each applicant examined of the results of the examination as to the respective applicant;

(7) certify as passing each applicant who obtains a grade of at least seventy-five percent on each subject upon which ~~[he]~~ the applicant is examined; providing that an applicant failing may apply for re-examination at the next scheduled examination date;

(8) keep a book of registration in which the name, address and license number of licensees shall be recorded, together with a record of license renewals, suspensions and revocations;

(9) grant, deny, renew, suspend or revoke licenses to practice optometry in accordance with the provisions of the Uniform Licensing Act for any cause stated in the Optometry Act;

(10) develop and administer qualifications for

underscored material = new
[bracketed material] = delete

1 certification for the use of [~~topical ocular pharmaceutical~~
2 ~~agents and oral~~] pharmaceutical agents as authorized in Section
3 61-2-10.2 NMSA 1978, including minimum educational requirements
4 and examination, as required by Section [~~61-2-10~~] 61-2-10.2
5 NMSA 1978 and provide the board of pharmacy with an annual list
6 of optometrists certified to use [~~topical ocular pharmaceutical~~
7 ~~agents and oral~~] pharmaceutical agents as authorized in Section
8 61-2-10.2 NMSA 1978; and

9 (11) provide for the suspension of an
10 optometrist's license for sixty days upon a determination of
11 use of pharmaceutical agents without prior certification in
12 accordance with Section [~~61-2-10~~] 61-2-10.2 NMSA 1978, after
13 proper notice and an opportunity to be heard before the board."

14 SECTION 3. Section 61-2-10.2 NMSA 1978 (being Laws 1995,
15 Chapter 20, Section 5, as amended) is amended to read:

16 "61-2-10.2. DESIGNATION OF [~~ORAL~~] PHARMACEUTICAL AGENTS--
17 CERTIFICATION FOR USE OF CERTAIN AGENTS.--

18 A. Subject to the provisions of the Optometry Act,
19 optometrists qualified and certified by the board may prescribe
20 or administer [~~the following classes of oral pharmaceutical~~
21 ~~agents:~~

22 (1) ~~anti-infective medications, not including~~
23 ~~antifungals;~~

24 (2) ~~anti-glaucoma medications, not including~~
25 ~~osmotic medications;~~

.199044.2

underscored material = new
[bracketed material] = delete

- 1 ~~(3) anti-allergy medications;~~
2 ~~(4) anti-inflammatory medications, not~~
3 ~~including oral corticosteroids and immunosuppression agents;~~
4 ~~and~~
5 ~~(5) analgesic medications, including schedules~~
6 ~~III through V controlled substances, as provided in the~~
7 ~~Controlled Substances Act]~~ all pharmaceutical agents for the
8 diagnosis and treatment of disease of the eye or adnexa;
9 provided that an optometrist:
10 (1) may prescribe hydrocodone and hydrocodone
11 combination medications;
12 (2) may administer epinephrine auto-injections
13 to counter anaphylaxis; and
14 (3) shall not prescribe any other controlled
15 substance classified in Schedule I or II pursuant to the
16 Controlled Substances Act.

17 B. The board shall issue certification for the use
18 of [~~oral~~] pharmaceutical agents as set forth in Subsection A of
19 this section to optometrists currently licensed by the board
20 [~~who are certified for the use of topical ocular pharmaceutical~~
21 ~~agents~~]. To be certified, an optometrist shall submit to the
22 board proof of having satisfactorily completed a course in
23 pharmacology as applied to optometry, with particular emphasis
24 on the administration of [~~oral~~] pharmaceutical agents for the
25 purpose of examination of the human eye, and analysis of ocular

.199044.2

underscored material = new
[bracketed material] = delete

1 functions and treatment of visual defects or abnormal
2 conditions of the human eye and its adnexa. The course shall
3 constitute a minimum of twenty hours of instruction in clinical
4 pharmacology, including systemic pharmacology as applied to
5 optometry, and shall be taught by an accredited institution
6 approved by the board.

7 C. ~~[As of July 1, 1996, all]~~ Applicants for
8 licensure shall meet the requirements for certification in the
9 use of ~~[diagnostic, topical therapeutic and oral]~~
10 pharmaceutical agents as set forth in the Optometry Act and
11 shall successfully complete the board's examination in
12 ~~[diagnostic, topical and oral]~~ pharmaceutical agents prior to
13 licensure.

14 D. The certification authorized by this section
15 shall be displayed in a conspicuous place in the optometrist's
16 principal office or place of business."

17 SECTION 4. Section 61-2-10.3 NMSA 1978 (being Laws 2003,
18 Chapter 274, Section 8) is amended to read:

19 "61-2-10.3. PRESCRIPTION FOR ~~[TOPICAL OCULAR~~
20 ~~PHARMACEUTICAL AGENT, ORAL]~~ PHARMACEUTICAL AGENT OR OPHTHALMIC
21 LENSES--REQUIRED ELEMENTS--AUTHORITY OF A PERSON WHO SELLS AND
22 DISPENSES EYEGLASSES.--

23 A. A prescription written for a ~~[topical ocular~~
24 ~~pharmaceutical agent or for an oral]~~ pharmaceutical agent shall
25 include an order given individually for the person for whom

.199044.2

underscored material = new
[bracketed material] = delete

1 prescribed, either directly from the prescriber to a pharmacist
2 or indirectly by means of a written or electronic order signed
3 by the prescriber, that bears the name and address of the
4 prescriber, [~~his~~] the prescriber's license classification, the
5 name and address of the patient, the name and quantity of the
6 agent prescribed and directions for its use and the date of
7 issue.

8 B. A prescription written for ophthalmic lenses
9 shall include:

10 (1) the dioptric power of spheres, cylinders
11 and prisms, the axes of cylinders, the position of the prism
12 base and, if so desired by the prescriber, the light
13 transmission properties and lens curve values;

14 (2) the designation of pupillary distance; and

15 (3) the name of the patient, the date of the
16 prescription, the expiration date of the prescription and the
17 name and address of the prescriber.

18 C. A person who sells and dispenses eyeglasses upon
19 the written prescription of a physician, surgeon or optometrist
20 may determine:

21 (1) the type, form, size and shape of
22 ophthalmic lenses;

23 (2) the placement of optical centers for
24 distance-seeing and near-work;

25 (3) the designation of type and placement of

underscoring material = new
[bracketed material] = delete

1 reading segments in multivision lenses;

2 (4) the type and quality of frame or mounting,
3 the type of bridge and the distance between lenses and the
4 type, length and angling of temples; and

5 (5) the designation of pupillary distance."

6 SECTION 5. Section 61-2-14 NMSA 1978 (being Laws 1973,
7 Chapter 353, Section 12, as amended) is amended to read:

8 "61-2-14. OFFENSES.--

9 A. A person who commits one of the following acts
10 is guilty of a fourth degree felony and upon conviction shall
11 be sentenced pursuant to the provisions of Section 31-18-15
12 NMSA 1978:

13 (1) practicing or attempting to practice
14 optometry without a valid current license issued by the board;

15 (2) using or attempting to use a [~~topical~~
16 ~~ocular pharmaceutical agent or an oral~~] pharmaceutical agent
17 that is regulated pursuant to the provisions of the New Mexico
18 Drug, Device and Cosmetic Act without having the certification
19 for its use issued by the board, unless the administration of
20 pharmaceutical agents is done under the direct supervision of a
21 licensed optometrist certified to administer the pharmaceutical
22 agents in accordance with the provisions of the Optometry Act;
23 or

24 (3) permitting a person in one's employ,
25 supervision or control to practice optometry or use

.199044.2

underscored material = new
[bracketed material] = delete

1 pharmaceutical agents described in Paragraph (2) of this
2 subsection unless that person is licensed and certified in
3 accordance with the provisions of the Optometry Act or unless
4 the administration of pharmaceutical agents is done under the
5 direct supervision of a licensed optometrist certified to
6 administer the pharmaceutical agents in accordance with the
7 provisions of the Optometry Act.

8 B. A person who commits one of the following acts
9 is guilty of a misdemeanor and upon conviction shall be
10 sentenced pursuant to the provisions of Section 31-19-1 NMSA
11 1978:

12 (1) making a willfully false oath or
13 affirmation where the oath or affirmation is required by the
14 Optometry Act;

15 (2) selling or using any designation, diploma
16 or certificate tending to imply that one is a practitioner of
17 optometry, unless one holds a license as provided by the
18 Optometry Act;

19 (3) refusing, after a request, to provide a
20 patient a copy of [~~his~~] the patient's eyeglasses prescription,
21 if the prescription is not over one year old;

22 (4) duplicating or replacing an ophthalmic
23 lens without a current prescription not more than two years old
24 or without a written authorization from the patient if the
25 prescription is not available;

.199044.2

underscored material = new
[bracketed material] = delete

1 (5) except for licensed optometrists, using
2 any trial lenses, trial frames, graduated test cards or other
3 appliances or instruments for the purpose of examining the eyes
4 or rendering assistance to anyone who desires to have an
5 examination of the eyes, but it is not the intent of this
6 paragraph to prevent ~~[any]~~ a school nurse, schoolteacher or
7 employee in public service from ascertaining the possible need
8 of vision services, if the person, clinic or program does not
9 attempt to diagnose or prescribe ophthalmic lenses for the eyes
10 or recommend any particular practitioner or system of practice;

11 (6) advertising the fabricating, adapting,
12 employing, providing, sale or duplication of eyeglasses or any
13 part ~~[thereof]~~ of them, but this paragraph does not preclude
14 the use of a business name, trade name or trademark not
15 relating to price or the use of the address, telephone number,
16 office hours and designation of the provider, in or at retail
17 outlets, on business cards, eyeglass cleaners and cases or in
18 news media or in public directories, mailings and announcements
19 of location openings or the use of the words "doctors'
20 prescriptions for eyeglasses filled" or "eyeglass repairs,
21 replacements and adjustments"; or

22 (7) selling of prescription eyeglasses or
23 contact lenses, frames or mountings for lenses in an
24 establishment in which the majority of its income is not
25 derived from being engaged in that endeavor."

.199044.2

underscoring material = new
~~[bracketed material]~~ = delete

1 SECTION 6. Section 26-1-2 NMSA 1978 (being Laws 1967,
2 Chapter 23, Section 2, as amended) is amended to read:

3 "26-1-2. DEFINITIONS.--As used in the New Mexico Drug,
4 Device and Cosmetic Act:

5 A. "board" means the board of pharmacy or its duly
6 authorized agent;

7 B. "person" includes an individual, partnership,
8 corporation, association, institution or establishment;

9 C. "biological product" means a virus, therapeutic
10 serum, toxin, antitoxin or analogous product applicable to the
11 prevention, treatment or cure of diseases or injuries of humans
12 and domestic animals, and, as used within the meaning of this
13 definition:

14 (1) a "virus" is interpreted to be a product
15 containing the minute living cause of an infectious disease and
16 includes filterable viruses, bacteria, rickettsia, fungi and
17 protozoa;

18 (2) a "therapeutic serum" is a product
19 obtained from blood by removing the clot or clot components and
20 the blood cells;

21 (3) a "toxin" is a product containing a
22 soluble substance poisonous to laboratory animals or humans in
23 doses of one milliliter or less of the product and, following
24 the injection of nonfatal doses into an animal, having the
25 property of or causing to be produced therein another soluble

.199044.2

1 substance that specifically neutralizes the poisonous substance
2 and that is demonstrable in the serum of the animal thus
3 immunized; and

4 (4) an "antitoxin" is a product containing the
5 soluble substance in serum or other body fluid of an immunized
6 animal that specifically neutralizes the toxin against which
7 the animal is immune;

8 D. "controlled substance" means a drug, substance
9 or immediate precursor enumerated in Schedules I through V of
10 the Controlled Substances Act;

11 E. "drug" means articles:

12 (1) recognized in an official compendium;

13 (2) intended for use in the diagnosis, cure,
14 mitigation, treatment or prevention of disease in humans or
15 other animals and includes the domestic animal biological
16 products regulated under the federal Virus-Serum-Toxin Act, 37
17 Stat 832-833, 21 U.S.C. 151-158, and the biological products
18 applicable to humans regulated under Federal 58 Stat 690, as
19 amended, 42 U.S.C. 216, Section 351, 58 Stat 702, as amended,
20 and 42 U.S.C. 262;

21 (3) other than food, that affect the structure
22 or any function of the human body or the bodies of other
23 animals; and

24 (4) intended for use as a component of
25 Paragraph (1), (2) or (3) of this subsection, but "drug" does

underscored material = new
~~[bracketed material] = delete~~

1 not include devices or their component parts or accessories;

2 F. "dangerous drug" means a drug, other than a
3 controlled substance enumerated in Schedule I of the Controlled
4 Substances Act, that because of a potentiality for harmful
5 effect or the method of its use or the collateral measures
6 necessary to its use is not safe except under the supervision
7 of a practitioner licensed by law to direct the use of such
8 drug and hence for which adequate directions for use cannot be
9 prepared. "Adequate directions for use" means directions under
10 which the layperson can use a drug or device safely and for the
11 purposes for which it is intended. A drug shall be dispensed
12 only upon the prescription or drug order of a practitioner
13 licensed by law to administer or prescribe the drug if it:

14 (1) is a habit-forming drug and contains any
15 quantity of a narcotic or hypnotic substance or a chemical
16 derivative of such substance that has been found under the
17 federal act and the board to be habit forming;

18 (2) because of its toxicity or other potential
19 for harmful effect or the method of its use or the collateral
20 measures necessary to its use is not safe for use except under
21 the supervision of a practitioner licensed by law to administer
22 or prescribe the drug;

23 (3) is limited by an approved application by
24 Section 505 of the federal act to the use under the
25 professional supervision of a practitioner licensed by law to

.199044.2

1 administer or prescribe the drug;

2 (4) bears the legend: "Caution: federal law
3 prohibits dispensing without prescription.";

4 (5) bears the legend: "Caution: federal law
5 restricts this drug to use by or on the order of a licensed
6 veterinarian."; or

7 (6) bears the legend "RX only";

8 G. "counterfeit drug" means a drug that is
9 deliberately and fraudulently mislabeled with respect to its
10 identity, ingredients or sources. Types of such pharmaceutical
11 counterfeits may include:

12 (1) "identical copies", which are counterfeits
13 made with the same ingredients, formulas and packaging as the
14 originals but not made by the original manufacturer;

15 (2) "look-alikes", which are products that
16 feature high-quality packaging and convincing appearances but
17 contain little or no active ingredients and may contain harmful
18 substances;

19 (3) "rejects", which are drugs that have been
20 rejected by the manufacturer for not meeting quality standards;
21 and

22 (4) "relabels", which are drugs that have
23 passed their expiration dates or have been distributed by
24 unauthorized foreign sources and may include placebos created
25 for late-phase clinical trials;

.199044.2

underscoring material = new
~~[bracketed material] = delete~~

1 H. "device", except when used in Subsection P of
2 this section and in Subsection G of Section 26-1-3, Subsection
3 L and Paragraph (4) of Subsection A of Section 26-1-11 and
4 Subsection C of Section 26-1-24 NMSA 1978, means an instrument,
5 apparatus, implement, machine, contrivance, implant, in vitro
6 reagent or other similar or related article, including any
7 component, part or accessory, that is:

8 (1) recognized in an official compendium;

9 (2) intended for use in the diagnosis of
10 disease or other conditions or in the cure, mitigation,
11 treatment or prevention of disease in humans or other animals;
12 or

13 (3) intended to affect the structure or a
14 function of the human body or the bodies of other animals and
15 that does not achieve any of its principal intended purposes
16 through chemical action within or on the human body or the
17 bodies of other animals and that is not dependent on being
18 metabolized for achievement of any of its principal intended
19 purposes;

20 I. "prescription" means an order given individually
21 for the person for whom prescribed, either directly from a
22 licensed practitioner or the practitioner's agent to the
23 pharmacist, including by means of electronic transmission, or
24 indirectly by means of a written order signed by the
25 prescriber, and bearing the name and address of the prescriber,

.199044.2

1 the prescriber's license classification, the name and address
2 of the patient, the name and quantity of the drug prescribed,
3 directions for use and the date of issue;

4 J. "practitioner" means a certified advanced
5 practice chiropractic physician, physician, doctor of oriental
6 medicine, dentist, veterinarian, euthanasia technician,
7 certified nurse practitioner, clinical nurse specialist,
8 pharmacist, pharmacist clinician, certified nurse-midwife,
9 physician assistant, prescribing psychologist, dental
10 hygienist, optometrist or other person licensed or certified to
11 prescribe and administer drugs that are subject to the New
12 Mexico Drug, Device and Cosmetic Act;

13 K. "cosmetic" means:

14 (1) articles intended to be rubbed, poured,
15 sprinkled or sprayed on, introduced into or otherwise applied
16 to the human body or any part thereof for cleansing,
17 beautifying, promoting attractiveness or altering the
18 appearance; and

19 (2) articles intended for use as a component
20 of any articles enumerated in Paragraph (1) of this subsection,
21 except that the term shall not include soap;

22 L. "official compendium" means the official United
23 States pharmacopoeia national formulary or the official
24 homeopathic pharmacopoeia of the United States or any
25 supplement to either of them;

1 M. "label" means a display of written, printed or
2 graphic matter upon the immediate container of an article. A
3 requirement made by or under the authority of the New Mexico
4 Drug, Device and Cosmetic Act that any word, statement or other
5 information appear on the label shall not be considered to be
6 complied with unless the word, statement or other information
7 also appears on the outside container or wrapper, if any, of
8 the retail package of the article or is easily legible through
9 the outside container or wrapper;

10 N. "immediate container" does not include package
11 liners;

12 O. "labeling" means all labels and other written,
13 printed or graphic matter:

14 (1) on an article or its containers or
15 wrappers; or

16 (2) accompanying an article;

17 P. "misbranded" means a label to an article that is
18 misleading. In determining whether the label is misleading,
19 there shall be taken into account, among other things, not only
20 representations made or suggested by statement, word, design,
21 device or any combination of the foregoing, but also the extent
22 to which the label fails to reveal facts material in the light
23 of such representations or material with respect to
24 consequences that may result from the use of the article to
25 which the label relates under the conditions of use prescribed

1 in the label or under such conditions of use as are customary
2 or usual;

3 Q. "advertisement" means all representations
4 disseminated in any manner or by any means, other than by
5 labeling, for the purpose of inducing, or that are likely to
6 induce, directly or indirectly, the purchase of drugs, devices
7 or cosmetics;

8 R. "antiseptic", when used in the labeling or
9 advertisement of an antiseptic, shall be considered to be a
10 representation that it is a germicide, except in the case of a
11 drug purporting to be or represented as an antiseptic for
12 inhibitory use as a wet dressing, ointment, dusting powder or
13 such other use as involves prolonged contact with the body;

14 S. "new drug" means a drug:

15 (1) the composition of which is such that the
16 drug is not generally recognized, among experts qualified by
17 scientific training and experience to evaluate the safety and
18 efficacy of drugs, as safe and effective for use under the
19 conditions prescribed, recommended or suggested in the labeling
20 thereof; or

21 (2) the composition of which is such that the
22 drug, as a result of investigation to determine its safety and
23 efficacy for use under such conditions, has become so
24 recognized, but that has not, otherwise than in such
25 investigations, been used to a material extent or for a

underscoring material = new
~~[bracketed material] = delete~~

1 material time under such conditions;

2 T. "contaminated with filth" applies to a drug,
3 device or cosmetic not securely protected from dirt, dust and,
4 as far as may be necessary by all reasonable means, from all
5 foreign or injurious contaminations, or a drug, device or
6 cosmetic found to contain dirt, dust, foreign or injurious
7 contamination or infestation;

8 U. "selling of drugs, devices or cosmetics" shall
9 be considered to include the manufacture, production,
10 processing, packing, exposure, offer, possession and holding of
11 any such article for sale and the sale and the supplying or
12 applying of any such article in the conduct of a drug or
13 cosmetic establishment;

14 V. "color additive" means a material that:

15 (1) is a dye, pigment or other substance made
16 by a process of synthesis or similar artifice or extracted,
17 isolated or otherwise derived, with or without intermediate or
18 final change of identity, from a vegetable, mineral, animal or
19 other source; or

20 (2) when added or applied to a drug or
21 cosmetic or to the human body or a part thereof, is capable,
22 alone or through reaction with other substances, of imparting
23 color thereto; except that such term does not include any
24 material that has been or hereafter is exempted under the
25 federal act;

.199044.2

underscored material = new
[bracketed material] = delete

1 W. "federal act" means the Federal Food, Drug and
2 Cosmetic Act;

3 X. "restricted device" means a device for which the
4 sale, distribution or use is lawful only upon the written or
5 oral authorization of a practitioner licensed by law to
6 administer, prescribe or use the device and for which the
7 federal food and drug administration requires special training
8 or skills of the practitioner to use or prescribe. This
9 definition does not include custom devices defined in the
10 federal act and exempt from performance standards or premarket
11 approval requirements under Section 520(b) of the federal act;

12 Y. "prescription device" means a device that,
13 because of its potential for harm, the method of its use or the
14 collateral measures necessary to its use, is not safe except
15 under the supervision of a practitioner licensed in this state
16 to direct the use of such device and for which "adequate
17 directions for use" cannot be prepared, but that bears the
18 label: "Caution: federal law restricts this device to sale by
19 or on the order of a _____", the blank to be filled with
20 the word "physician", "physician assistant", "certified
21 advanced practice chiropractic physician", "doctor of oriental
22 medicine", "dentist", "veterinarian", "euthanasia technician",
23 "certified nurse practitioner", "clinical nurse specialist",
24 "pharmacist", "pharmacist clinician", "certified nurse-midwife"
25 or "dental hygienist", optometrist or with the descriptive

.199044.2

underscoring material = new
~~[bracketed material] = delete~~

1 designation of any other practitioner licensed in this state to
2 use or order the use of the device;

3 Z. "valid practitioner-patient relationship" means
4 a professional relationship, as defined by the practitioner's
5 licensing board, between the practitioner and the patient;

6 AA. "pedigree" means the recorded history of a
7 drug; and

8 BB. "drug order" means an order either directly
9 from a licensed practitioner or the practitioner's agent to the
10 pharmacist, including by means of electronic transmission or
11 indirectly by means of a written order signed by the licensed
12 practitioner or the practitioner's agent, and bearing the name
13 and address of the practitioner and the practitioner's license
14 classification and the name and quantity of the drug or device
15 ordered for use at an inpatient or outpatient facility."

16 SECTION 7. REPEAL.--Section 61-2-10 NMSA 1978 (being Laws
17 1977, Chapter 30, Section 3, as amended) is repealed.